Musculoskeletal (MSK) conditions already represent an enormous burden for the healthcare industry, affecting 1 in 2 adults at an estimated cost of $420 billion dollars annually. More troubling still, MSK conditions are on the rise and expected to increase by 115% by 2050, impacting more than 1 billion people. The surge in MSK conditions is multi-faceted, linked to global aging and rising disease rates. Some speculate that the COVID-19 pandemic had a larger impact that previously thought on the MSK system, where a lasting inflammatory response in the form of myalgias and arthralgias are seen in some patients. The need for safe, high-quality MSK condition management is more important than ever, an aim that can be achieved through evidence-based interventions to improve outcomes, reduce healthcare costs, and improve the quality of life for those suffering.
